SEC Form 4 · accession 0001209191-15-077347

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Oct 28, 2015

Accepted (ET)

Oct 30, 2015 · 10:31 am EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Oct 28, 2015	M	10,400	$35.64	A	355,684	D
Common Stock^F2,F3	Oct 28, 2015	S	1,200	$117.25	D	354,484	D
Common Stock^F2,F4	Oct 28, 2015	S	2,144	$118.30	D	352,340	D
Common Stock^F2,F5	Oct 28, 2015	S	4,356	$119.10	D	347,984	D
Common Stock^F2,F6	Oct 28, 2015	S	2,600	$120.18	D	345,384	D
Common Stock	Oct 28, 2015	S	100	$121.47	D	345,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	122,700	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F7	$35.64	Oct 28, 2015	M	10,400	D	—	Feb 1, 2016	Common Stock	10,400	136,000	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $117.25 (range $116.65 to $117.53).
F4Open market sales reported on this line occurred at a weighted average price of $118.30 (range $117.65 to $118.52).
F5Open market sales reported on this line occurred at a weighted average price of $119.10 (range $118.71 to $119.64).
F6Open market sales reported on this line occurred at a weighted average price of $120.18 (range $119.71 to $120.65).
F7Fully vested.